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Context:Metastatic disease is responsible for the majority of endocrine cancer deaths. New ther-
apeutic targets are urgently needed to improve patient survival rates.
Objective: The proto-oncogene PTTG1-binding factor (PBF/PTTG1IP) is overexpressed in multiple
endocrine cancers and circumstantially associated with tumor aggressiveness. This study aimed to
understand the role of PBF in tumor cell invasion and identify possible routes to inhibit its action.
Design, Setting, Patients, and Interventions: Thyroid, breast, and colorectal cells were transfected
with PBF and cultured for in vitro analysis. PBF and cortactin (CTTN) expression was determined in
differentiated thyroid cancer and The Cancer Genome Atlas RNA-seq data.
Primary OutcomeMeasure: Pro-invasive effects of PBFwere evaluated by 2D Boyden chamber, 3D
organotypic, and proximity ligation assays.
Results: Our study identified that PBF and CTTN physically interact and co-localize, and that this
occurs at the cell periphery, particularly at the leading edgeofmigrating cancer cells. Critically, PBF
induces potent cellular invasion and migration in thyroid and breast cancer cells, which is entirely
abrogated in the absence of CTTN. Importantly, we found that CTTN is over-expressed in differ-
entiated thyroid cancer, particularly in patients with regional lymph node metastasis, which sig-
nificantly correlates with elevated PBF expression. Mutation of PBF (Y174A) or pharmacological
interventionmodulates the PBF: CTTN interaction and attenuates the invasive properties of cancer
cells.
Conclusion:Our results demonstrate a unique role for PBF in regulating CTTN function to promote
endocrine cell invasion and migration, as well as identify a new targetable interaction to block
tumor cell movement. (J Clin Endocrinol Metab 101: 4551–4563, 2016)
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New cancer targets, which abrogate the movement oftumor cells, will be critical to improving future can-
cer survival rates worldwide (1). Of central importance in
attaining this goal is to better understand how tumors
exhibit uncontrolled and invasive cellular growth, which
is modulated through the interaction of malignant cells
with the extracellular matrix, the vasculature, and the im-
mune system (2, 3). Considerable attention has focused on
the regulation of actin assembly at the leading edge of
malignant cells, a process integral to the formation of pro-
trusive structures such as invadopodia (4). It is known, for
instance, that a multitude of diverse signaling molecules
such as RhoA can control actin cytoskeletal dynamics in
migrating cells (5). However, factors that influence actin
polymerization in the tumor environment are still poorly
understood.
Cortactin (CTTN) is a scaffold protein active predom-
inantly at the periphery of cells which promotes actin po-
lymerization by binding and activating the Arp2/3 com-
plex (6), as well as inhibiting debranching of actin
networks (7). In this way, CTTN is able to exert a potent
influence upon cell movement and invasion (8–10). In-
deed, overexpression of CTTN is associated with in-
creased cellular motility and invasiveness in multiple can-
cer settings (8, 9). CTTN function is multifaceted and has
been linked to numerous processes, including vesicular
trafficking (8, 11), focal adhesion dynamics (12) and ex-
tracellular matrix secretion (13). These studies emphasize
the importance of CTTN as a key player in aggressive
cancersbut furtherwork is required toestablish theprecise
role of CTTN in different tumor settings.
Modulators of the complex processes by which cells
invade, migrate, and metastasize continue to be identified
(14). We initially characterized a potential role for the
proto-oncogene PTTG1-binding factor (PBF/PTTG1IP)
in breast cancer cell invasion in vitro (15). Subsequently,
three different studies have circumstantially linked PBF to
the process of tumor invasion andmetastasis in vivo. First,
high PBF expression was correlated with distant metasta-
sis at diagnosis, tumor node metastasis (TNM) stage and
disease-specific survival in a large series of papillary thy-
roid cancers (16). Secondly, high PBF promoter activity
was associatedwithpoorer clinical outcomeand increased
metastatic risk in breast cancer (17). Thirdly, colorectal
tumors with higher PBF protein expression demonstrated
greater vascular invasion (18). Thus, it is possible that PBF
is integral to tumor cell invasion in vivo.
PBFwas first identified as a type 1A integralmembrane
protein (IMP) (19). IMPs with cytosolic domains can act
as anchors for cytoskeletal proteins or be involved with
intracellular signaling. Its best described role however lies
in binding the sodium iodide symporter NIS and regulat-
ing its subcellular localization within thyroid cells (20,
21). PBF also interactswith the tumor suppressor p53 (18,
22) and the protein kinase Src (23). In particular, PBF is a
phospho-protein and interaction with Src elicits phos-
phorylation at tyrosine (Y) residue 174. This residue has
a potential functional duality as it forms the first residue
of a consensus YXX internalization motif. However,
althoughpY174 is enrichedat theplasmamembrane (PM)
(23), the precise relationship between PBF phosphoryla-
tion and intracellular trafficking of its binding partners
requires further investigation.
Given the emerging roles of PBF in cancer, particularly
as a proto-oncogene, here we studied its role in migration
and metastasis. We conducted mass spectrometry in thy-
roid cancer cells to map the full range of interactions with
PBF and identified CTTN as our top hit. As CTTN has a
well described role in cellmigration and tumormetastasis,
we assessed whether the interaction between CTTN and
PBF was functional. Extensive data are presented validat-
ing and delineating the interaction between the two pro-
teins.Thuswe identify anew functional bindingpartner of
CTTN, and propose a novel mechanism whereby PBF
binds CTTN close to the PM to facilitate cellular move-
ment.Modulation of PBF activitymay therefore represent
a promising new target for addressing tumor cell invasion
and migration.
Materials and Methods
Human tissue and cell culture
Human thyroid sampleswere obtainedwith local ethics com-
mittee approval and informed patient consent. Breast (MCF-7,
MDA-MB-231) and thyroid (TPC-1, SW1736) cell lines were
maintained in RPMI 1640 (Life Technologies). HCT116 cells
were maintained in McCoy’s 5A (Life Technologies), whereas
HeLa and NIH3T3 cells were maintained in DMEM (Sigma-
Aldrich). All media was supplemented with 10% fetal bovine
serum,penicillin (105U/L), and streptomycin (100mg/L).All cell
lines were obtained from the European Collection of Authenti-
cated Cell Cultures, except TPC-1 and SW1736, which were
kindly provided by Dr Rebecca Schweppe (University of Colo-
rado). Cells were cultured as recommended at low passage and
authenticated by short tandem repeat analysis (DNA Diagnos-
tics Centre). Stable cell lines were constructed as described pre-
viously (36). Further information on cell lines (Supplemental
Table 1) anda summaryof endogenousPBFandCTTNlevels are
provided (see Supplemental Figure 13).
Datasets
Normalized gene expression data generated using the Illu-
minia RNA-seq platform and clinical information was down-
loaded from cBioPortal (37, 38). Gene expression values were
transformed as X  log2(X  1) where X represents the nor-
malized fragments per kilobase transcript per million mapped
reads (FPKM) values. For matched normal (N) and tumor (C)
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pairs relative fold-changes (FC) were transformed as log2FC 
log2(C)  log2(N) where C and N represent normalized FPKM
values. Transcriptome datasets were selected for tumors with
TNM staging of T1–3N0 (nonmetastatic) or T1–3N1 (lymph
node metastasis). Transcriptomic and clinical information was
analyzed for 326 patients with thyroid cancer.
Nucleic acids and transfection
Plasmids containing PBF cDNA with a hemagglutinin (HA)
tag have been described (37). The QuikChange Site-Directed
Mutagenesis Kit (Stratagene) was used to generate Y174A PBF-
HA. Plasmids expressing human Myc-CTTN (No. RC223259)
and GFP-PBF (No. RG202109) were purchased from Origene
(Rockwell). CTTN siRNAs (s4666 and s4667) and control
siRNA (AM4635) were purchased from Invitrogen. Plasmid
DNA and siRNA transfections were performed with TransIT-
LT1 (Geneflow) and siPORT (Invitrogen) using standard
protocols.
Western blotting and antibodies
Western blot analyses was performed as described previously
(21, 31). Blots were probed with specific antibodies against PBF
[Eurogentec; (15, 21)], pY174 PBF [CovalAb (23)], HA (16B12;
Covance Research Products), HA (sc-805; Santa Cruz), Myc
(No. 2276; Cell Signaling Technology), CTTN (AB3887;Merck
Millipore), pCTTN (Tyr421) (No. 4569; Cell Signaling Tech-
nology), and -actin (AC-15; Sigma-Aldrich). AlexFluor-conju-
gated antibodies (488, 555, 594 and 647) were purchased from
Molecular Probes.
Immunostaining and proximity ligation assay
Immunofluorescence was performed as described previously
(21). AZeiss confocal LSM510microscopewas used to perform
confocalmicroscopy. Imageswereprocessedwith ImageJ (http://
imagej.net/Coloc_2) to determine Pearson’s colocalization co-
efficients (39). Epifluorescent microscopy was performed on a
Zeiss Axioplan fluorescent microscope. Human thyroid tissue
was immunostained using the Novolink polymer detection kit
(Leica) as per manufacturer’s instructions. Slides were viewed
under a light microscope (Zeiss) and images captured using Ax-
iovision software. The Duolink in situ proximity ligation assay
(PLA) was performed according to manufacturer’s instructions
(Olink Bioscience).
Invasion assays and live cell imaging
2DBoyden chamber invasion assays were performed accord-
ing to manufacturer’s instructions using BioCoat growth factor
reduced matrigel invasion chambers (BD Biosciences). 3D orga-
notypic invasion assays were performed using standard proto-
cols withMDA-MB-231 cells and cancer-associated fibroblasts.
Invasion parameters were calculated as described previously
(40). Classical scratch wound healing assays were performed
using standard protocols and live cell images takenwith aNikon
A1R Inverted Confocal/TIRF microscope.
Mass spectrometry
PBF-interacting proteins were isolated by coimmunoprecipi-
tation (anti-mHA antibody) and separated by SDS-PAGE. Fol-
lowing destaining, proteins were reduced, alkylated, and
trypsinizedbefore undergoingHPLCandAmaZonETD ion trap
and tandem mass spectrometry (Bruker Daltronics). Mass spec-
trographs were analyzed via the Mascot search engine (Matrix
Science) and ProteinScape (Bruker). Multiple runs were per-
formed to identify consistent interactors.
RNA extraction and qRT-PCR
Total RNA was extracted from human thyroid tissue using
the RNeasy FFPE kit (QIAGEN) as per manufacturer’s instruc-
tions. Expression of specific mRNAs was determined on a 7500
Real-time PCR system (Applied Biosystems) using the Quanti-
Tect Probe RT-PCR kit (QIAGEN). Relative expression was de-
terminedusing the2Ctmethod.TaqManassaysaredescribed
(Supplemental Table 3).
Statistical analysis
All results were obtained from triplicate experiments unless
otherwise indicated. Data were analyzed using SigmaStat (SPSS)
and displayed as mean  SEM. Statistical analyses were per-
formedwith the Student t test or the nonparametricMann-Whit-
ney U test. We used Spearman’s rank-based correlation to de-
termine associations between TCGA datasets. Significance was
taken as P  .05.
Results
PBF induces cellular invasion and binds CTTN
The precise role of PBF in tumor cell invasion remains
poorly understood in breast, thyroid, and colorectal can-
cer cells (15–18). We therefore sought to investigate the
ability of PBF to induce invasion across a panel of cancer
cells (SupplementalTable1).Thepotentproinvasive effect
of PBFoverexpressionwas evident in2Dassays inMCF-7,
TPC-1, and HCT116 cell lines (Figure 1A and Supple-
mental Figure 1A; P  .05). We further performed 3D
organotypic invasion assays inMDA-MB-231 breast cells
and showed that PBF is proinvasive in vitro with signifi-
cantly increased invasion parameters (Figure 1B and Sup-
plemental Figure 1B; P  .01). Cell invasion is related to
and encompasses cell migration. We therefore next eval-
uated cell migration to determine whether elevated levels
ofPBFarepromigratory.AstablemurineNIH3T3cell line
overexpressing PBF (	24-fold increase in PBF mRNA)
demonstrated that PBF induced significantwound healing
compared with controls at both 4 and 6 hours postrecov-
ery (Figure 1C).
Having established that PBF exhibits a broad and con-
sistent role in promoting cell invasion, we next performed
mass spectrometry in thyroidal TPC-1 and K1 cell lines to
identify possible binding partners of PBF with roles in cell
motility. From our in vitro studies we identified CTTN,
which was the top hit across all runs (12 peptide hits;
average score per peptide 40.0; n 4 runs; Supplemen-
tal Table 2). Given CTTN’s pivotal role in cell migration
and invasion, we appraised the mass spectrometry data
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Figure 1. Proinvasive effect of PBF and specific binding to CTTN. A, Representative 2D Boyden cell invasion assays from three independent
experiments showing increased invasion of MCF-7 and TPC-1 cells transfected with PBF compared with VO. Results are mean  SEM.
Representative photomicrographs shown above. B, Representative 3D organotypic invasion assays in MDA-MB-231 cells transfected with VO or
PBF. Box-whisper plots show quantification of invasion index and area of MDA-MB-231 cells in the presence () or absence () of cancer-
associated fibroblasts. Statistics analyzed using Mann-Whitney U test. C, Representative images of scratch wound assay from three independent
experiments in NIH3T3 cells stably transfected with VO or PBF at 4 and 6 h postrecovery with percent wound recovery shown (graph). Results are
mean  SEM. *, P  .05; **, P  .01; ***, P  .001. D, Representative Co-IP assays from three independent experiments showing specific
interaction (*) between myc-tagged CTTN and HA-tagged PBF in MCF-7 and HeLa cells. E, Proximity ligation assays (PLA) assays showing specific
interaction between PBF-HA and myc-CTTN in MCF-7, MDA-MB-231, and TPC-1 cells. Red fluorescent spots indicate specific interactions. White
indicates DAPI nuclear staining. Magnification, 63
. Scale bars, 10 M.
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using coimmunoprecipitation (co-IP) assays in MCF-7
andHeLa cells. These confirmed a specific interaction be-
tween PBF andCTTN in vitro (Figure 1D).We challenged
our findings with the separate methodology of proximity
ligation assays (PLAs); further demonstrating specific
binding between CTTN and PBF predominantly toward
the periphery of cells (Figure 1E). No specific interactions
were apparent in control PLAassays (Supplemental Figure
1C).
CTTN and PBF colocalize during cell migration
In basal conditions inactive CTTNdiffuses throughout
the cytoplasm. However, in migrating cells CTTN local-
izes to the cell cortex to mediate actin filament assembly
and promote protrusion formation at the leading edge
(10). We next examined CTTN and PBF by immunoflu-
orescence in thyroid SW1736 cells, which revealed CTTN
expression predominantly within intracellular vesicles
and at the PM(Figure 2AandSupplemental Figure 2). PBF
expressionwasmainly vesicular, and partially overlapped
with CTTN, although not consistently within the same
vesicular structures. However, colocalization was pro-
nounced at discrete PM regions where CTTN expression
was concentrated (Figure 2A and Supplemental Figure 2).
Confocal image analysis confirmed significant overlap at
intense ‘hot spots’ of PBF:CTTN colocalization at the PM
(Figure 2A and Supplemental Figure 2B; see Pearson’s co-
efficient). Together these results demonstrate that CTTN
colocalizes with PBF predominately at the PM.
To further investigate the ability of PBF to promote cell
migration we performed live cell migration assays in
TPC-1 cells transfected with GFP-tagged PBF. Our results
demonstrated an overall induction in cellularmigration of
approximately 40% in the presence of PBF (Figure 2, B–D;
P .01).We next determined the colocalization of CTTN
and PBF during the process of cellular migration in
scratch-wound assays. Our results showed that both pro-
teins had significant colocalization at the leading edge of
actively migrating MDA-MB-231 cells (Figure 2E and
Supplemental Figure 3A). Again, to determine whether
such colocalization was indicative of specific binding, we
carried out PLA assays, which revealed that as TPC-1 and
MDA-MB-231 cells migrate they are characterized by
CTTN and PBF binding, particularly at the leading edge
(Figure 2F and Supplemental Figure 3B). Thus, CTTN
binds PBF in vitro, a process that occurs in those cells
actively undergoing migration.
CTTN is elevated in differentiated thyroid cancer
and correlates with PBF
Although CTTN expression has previously been inves-
tigated in breast cancer (24), it has not been addressed in
differentiated thyroid cancer (DTC). In a series ofmatched
tumor and normal DTC specimens, CTTN mRNA
showed a significant 1.5-fold induction in tumors com-
pared with matched normal thyroid (Figure 3A; P  .05;
n  43). CTTN expression was also increased in addi-
tional DTC specimens (Figure 3B), with a significant in-
duction in CTTN protein evident in thyroid tumors (Fig-
ure3C;	2.5-fold induction).CTTNwasalsoabundant in
DTC as determined through immunohistochemistry (Fig-
ure 3D), seeming to be generally cytoplasmic within thy-
roid epithelial cells.
We next determined the association between CTTN
and PBF mRNA in DTC and showed a positive and sig-
nificant correlation (Figure 3E; P .014; rs 0.373; n
43). The origin of this correlation in expression between
CTTN and PBF was obscure as transfection of PBF failed
to modulate protein levels of CTTN, and vice versa (Sup-
plemental Figure 4). We therefore further evaluated
CTTN and PBF expression in papillary thyroid cancer
(PTC) by RNA-seq (TCGA). Consistent with our initial
observations, we found a significant increase in CTTN
expression (Figure 3F) in both nonmetastatic (N0; P 
5.6
1017; n  121) and metastatic PTC (N1; P 
7.5
1027; n 205) comparedwith normal thyroid (n
59), as well as in different-sized tumors (Figure 3F), which
was associated with subgroups of driver mutations (Sup-
plemental Figure 5A). Similarly, PBF expression (Figure
3G) was induced in nonmetastatic (N0; P  1.0
107;
n  121) and metastatic PTC (N1; P  8.5
1013; n 
205). Importantly, we again found a strong correlation
between CTTN and PBF expression in PTC (Figure 3H;
P 4.7
108; rs 0.299; n 326) and normal thyroid
(Supplemental Figure 5B). CTTN and PBF expression in
matched tumor/normal samples (n  59) confirmed a
strong correlation pattern (Supplemental Figure 5C; P 
2.74
106; rs  0.564).
Of particular significance, CTTN expression (Figure
3F) was higher in invasive metastatic PTC (N1; P 
3.6
105) than in nonmetastatic PTC (N0). TCGA clin-
ical data also showed that higher CTTN expression was
associated with stage IVA PTC (Figure 3I; P  .01), re-
currence/progressed disease (Supplemental Figure 6; P 
.029) and frequency of the BRAFmutation (Supplemental
Figure 7;P .001). Together our results demonstrate that
CTTN is overexpressed in thyroid cancer, particularly in
the most aggressive forms, and significantly correlates
with PBF expression.
CTTN mediates the influence of PBF on cell
invasion
There have been inconsistent reports on the role of
CTTN in cell motility, with a lack of involvement in the
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migration of CTTN-depleted mouse
embryonic fibroblasts (25), as well
as in 293T cells overexpressing
CTTN (26). Given the interaction
between CTTN and PBF, as well as
significant correlations in thyroid
cancer, we next depleted CTTN to
determine the dependence of PBF on
CTTN to promote cellular invasion.
Critically, knockdown of CTTN by
two different CTTN siRNAs (Figure
4, A and B) was associated with a
significant reduction in the endoge-
nous invasive capacity of SW1736
(P  .01), HCT116 (P  .001), and
MCF-7 cells (P  .01) transfected
with PBF. Of importance, the inva-
sive capacity of CTTN-depleted cells
transfected with PBF was equivalent
(P  NS) or lower (P  .05) than
vector-only (VO) control cells simi-
larly depleted of CTTN (Figure 4B).
Western blotting confirmed the re-
duction of endogenous CTTN pro-
tein by CTTN siRNA in all three cell
lines, as well as exogenous PBF ex-
pression (Figure 4C). Together these
results provide compelling evidence
that the potent induction of cell in-
vasion by PBF is driven in its entirety
via CTTN.
Phosphorylation modulates the
functional interaction of PBF
with CTTN
Phosphorylation at residue Y174
(Figure 5A; pY174) is critical to the
interaction of PBF with thyroid-en-
riched NIS at the PM and its subse-
quent intracellular transport (23).
We therefore investigated whether
the phosphorylation status of PBF
might influence its interaction with
CTTN. To explore this we charac-
terized endogenous CTTN and
pY174PBF,whichdemonstrated co-
localization in MCF-7 and HeLa
cells predominantly at the PM (Fig-
ure 5B), with significant overlap in-
dicatedby confocalmicroscopy (Fig-
ure 5C and Supplemental Figure 8;
see Pearson’s coefficient). Endoge-
Figure 2. PBF and CTTN colocalize at the leading edge in actively migrating cells. A,
Representative confocal images showing endogenous CTTN (green), exogenous PBF (red) and
colocalization (yellow) in SW1736 and MDA-MB-231 cells. Framed areas in merge images are
magnified in right panels and Pearson’s colocalization coefficients indicated. Magnification,
100
. Scale bars, 20 M. B, Representative image of live cell migration assay in TPC-1 cells
transfected with either GFP-tagged PBF or GFP-VO and tracked over 16.5 h. Photomicrographs
show the tracks of individual cells over time. Boxed areas are magnified (right panels). C,
Representation of individual tracks within one movie illustrate the further distances traveled by
PBF-transfected cells. D, Quantification of mean cell migration rate (m/h) of TPC-1 cells (n  79
VO vs n  63 PBF cells). E, Representative confocal images showing endogenous CTTN (green),
exogenous PBF (red) and colocalization (yellow) in MDA-MB-231 cells. Scratch wound migration
assays were halted at 4 h. White arrows indicate direction of cell movement. Magnified image
from framed area in merge shown in lower right panel and Pearson’s colocalization coefficients
indicated. F, PLA assays in TPC-1 and MDA-MB-231 cells halted during scratch wound assays
showing specific binding between CTTN and PBF (red dots), predominately at the leading edge of
migrating cells. Arrows indicate direction of wound healing. White indicates DAPI nuclear stain.
Magnification, 63
. Scale bars, 10 M.
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Figure 3. Elevated CTTN expression in thyroid cancer. A, Quantification of CTTN mRNA expression in differentiated thyroid cancer (DTC) relative
to matched normal tissue (n  43). Data represented as a scatter plot. Results are mean  SEM. *, P  .05. B and C, Western blot analysis of
CTTN expression in DTC (C1–6) and normal tissue (N1–3) with quantification of relative protein levels (C). Results are mean  SEM. *, P  .05. D,
Representative images of CTTN immunostaining in DTC and normal thyroid (20
 magnification). CTTN immunostaining was generally cytoplasmic
(black arrowhead, high power insert). Scale bars, 100 M. E, Scatterplot showing a significant correlation between CTTN and PBF mRNA (CT
values) in DTC. P  .014; rs  0.373; n  43 (Spearman rank correlation). F, G, CTTN and PBF expression (TCGA) in nonmetastatic (N0; n  121)
and metastatic (N1; n  205) PTC (left) vs normal thyroid (n  59), as well as in PTC of different tumor size T1–T3 (right). Data represented in box-
whisper plots. *, P  .05; **, P  .01; ***, P  .001 (Mann-Whitney U test). H, Scatter plot showing correlation between CTTN and PBF
expression (TCGA) in PTC (P  4.7
108; rs  0.299; n  326; Spearman rank correlation). I, Association of high (Q4) and low (Q1) CTTN
expression with neoplasm staging in PTC (n  80–82 per quartile). *, P  .05.
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nous PLA (Figure 5D) and co-IP (Figure 5E) assays con-
firmed that pY174 PBF specifically associates with
CTTN; thus physiological binding is plausible for res-
idue pY174 inmodulating the PBF:CTTN interaction at
the PM.
The involvement of pY174 was next examined using
PBF mutant Y174A, which disrupts phosphorylation at
this residue and accumulates PBF at the PM by abolishing
an internalization motif (23). Here we observed pro-
nounced colocalization between Y174A PBF-HA and
Figure 4. Depletion of CTTN ablates the ability of PBF to induce cellular invasion. A, Representative photomicrographs of 2D Boyden assay
chamber cell invasion experiments in SW1736, HCT116, and MCF-7 cells transfected with VO or PBF, and then treated with specific siRNAs for
CTTN (siRNA 1 and 2) or control siRNA (CON). B, Quantification of number of invading cells per well from 2D Boyden assay described in panel A.
Results expressed as mean  SEM from three independent experiments. *, P  .05; **, P  .01; ***, P  .001. C, Western blot analysis of CTTN
and PBF-HA expression in response to siRNA treatments as outlined in panel A. Graph (bottom) shows quantification of CTTN protein levels relative
to -actin from siRNA experiments in SW1736 cells. Data presented as mean CTTN levels  SEM from three independent experiments. *, P  .05;
**, P  .01; ***, P  .001.
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Figure 5. Involvement of Y174 in colocalization and binding of PBF with CTTN. A, Schematic of the protein domain structure of PBF showing the
relative position of the YARF internalization motif. Boxed area highlights the alanine substitution at the Y174 residue in Y174A PBF. B,
Representative immunofluorescence images showing subcellular colocalization (merge image, yellow) of endogenous CTTN (green) and
endogenous pY174 PBF (red) in MCF-7 and HeLa cells. Intense “hot spots” of colocalization are outlined (yellow boxes). C, Confocal images
showing colocalization (merge, yellow) between endogenous CTTN (green) and endogenous pY174 PBF (red) in MCF-7 cells. Framed areas in
merge images are magnified and Pearson’s colocalization coefficients are indicated. D, PLA assays showing specific interaction between
endogenous CTTN and endogenous pY174 PBF in HeLa cells. Red fluorescent spots indicate specific interactions. Framed areas are magnified in
lower panels. Scale bars, 10 M. E, Representative Co-IP assays showing specific interaction between endogenous CTTN and endogenous pY174
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myc-CTTN at the PM, and reduced intracellular vesicular
PBF compared with wild-type (WT) PBF (Figure 5F and
Supplemental Figure 9). Interestingly, co-IP studies re-
vealed that alanine substitution at residue Y174 was as-
sociated with markedly increased CTTN-binding (Figure
5G; 	2-fold; P  .05). PLA assays in TPC-1 and MD-
MBA-231 cells further suggested a strong interaction be-
tween Y174A PBF-HA and myc-CTTN (Figure 5H).
Wenext investigatedwhether the invasive properties of
cells might be attenuated by modulating the phosphory-
lation status of PBF. Firstly, 2D Boyden chamber assays
revealed that Y174A PBF was unable to stimulate cellular
invasion in TPC-1 and MCF-7 cells (Figure 6A and Sup-
plemental Figure 10; PNS). These data were appraised
in 3D organotypic assays in MDA-MB-231 cells, which
confirmed the lack of cell invasion with Y174A PBF (Fig-
ure 6B). Both PBF and CTTN are phosphorylated by Src
at residues Y174 and Y421, respectively (9, 23). Treat-
ment with the Src kinase inhibitor dasatinib reduced
CTTN phosphorylation by 30–50% and inhibited PBF:
CTTN binding by approximately 50% (Figure 6C; P 
.001). Y174APBF again boundCTTNwith higher avidity
than WT PBF. Critically, dasatinib also significantly re-
pressed binding between Y174A PBF and CTTN (Figure
6C; P  .001). In scratch wound assays, stable overex-
pression of Y174A PBF in MCF-7 cells was associated
with significantly decreased wound healing compared
with PBF (Figure 6D; P  .05). Importantly, dasatinib
treatment inhibited wound healing of MCF-7 cells over-
expressing WT PBF and Y174A PBF (Figure 6D and Sup-
plemental Figure 11; P  .05). Subsequent studies dem-
onstrated that the invasive properties of dasatinib-treated
TPC-1 cells correlated with PBF phosphorylation status
(Supplemental Figure 12).
Altogether these results demonstrate that tyrosine
phosphorylation is critical to the functional interaction of
PBF with CTTN in promoting tumor cell invasion. As
CTTNand PBF colocalize at the leading edge ofmigrating
cells, our data provides new mechanistic insights into
blocking the movement of cancer cells by therapeutic tar-
geting of this interaction. A schematic representation of
our findings is presented in Figure 6E.
Discussion
Differentiated thyroid cancer has a 5-year survival rate of
98.1%, but this decreases dramatically to 55.3% in
patients with distant metastases (http://seer.cancer.gov/
statfacts/html/thyro.html). The statistics are equally un-
promising inmetastatic breast cancer,where patients have
a 5-year survival rate of just 26.3%. In general, given that
it is the metastatic recurrence—and not the primary tu-
mor—that ultimately proves fatal, themetastatic pathway
requires continued investigation to establish new thera-
peutic targets. Through extensive mass spectrometry we
identified the proto-oncogene PBF as a new binding part-
ner of CTTN—a critical regulator of actin-cytoskeletal
dynamics and associated with tumor aggressiveness. A
clear interaction between PBF and CTTN at the cell pe-
riphery was evident by PLA analysis, which was further
validated by co-IP and immunofluorescence assays. Im-
portantly, functional CTTN expression was needed in or-
der for PBF to induce invasion. Our current study there-
fore demonstrates that the proinvasive and promigratory
action of PBF is contingent upon CTTN.
Expression of PBF has been circumstantially associated
with metastasis in patients with breast (17) and thyroid
cancer (16), and we recently reported that patients with
colorectal cancer who demonstrate extramural vascular
invasion have significantly higher PBF expression (18).
However, these associations have not been appraised for
causality, and the in vitro mechanisms by which PBF in-
duces tumor cell invasion are unclear. In the present study
we therefore utilized established thyroid, breast and colo-
rectal models to address the mechanism by which PBF
induces cell movement. A remarkable finding was that
PBF consistently induced promigratory and proinvasive
phenotypes across a panel of different cell types. Our re-
sults therefore imply that PBF may represent a novel
marker of the ability of cells to escape tumors and invade,
which provides further insight for the recent identification
of PBF as a central driver gene in human cancers across
multiple tumor types including thyroid (27).
CTTN expression has not been determined before in
human thyroid tumors. In this study analysis ofDTCspec-
imens revealed that CTTN expression, whereas variable,
was elevated in approximately two thirds of tumors. Im-
portantly, analysis of a large clinically annotated TCGA
dataset for PTC confirmed that CTTN was increased, es-
pecially in caseswith lymph nodemetastasis. A significant
positive association between PBF and CTTNmRNA was
also evident in DTC specimens, as well as in TCGA, sug-
gesting perhaps a commonality of gene regulation. This
would not likely result from direct transcriptional regu-
lation via either binding partner as neither CTTNnor PBF
Figure 5. (Continued). PBF in MCF-7 and HeLa cells. F,
Representative immunofluorescence images showing colocalization
(merge, yellow) between myc-CTTN (green) and either WT PBF-HA
(red) or Y174A PBF-HA (red) at the PM in SW1736 cells. Magnification,
100
. Scale bars, 20 M. G, Co-IP assays showing increased binding
(*) between myc-tagged CTTN and Y174A PBF vs WT PBF. Graph
(right) shows quantification of PBF protein levels relative to -actin
from three independent experiments in HeLa cells. Data expressed as
mean PBF levels  SEM. *, P  .05. H, PLA assays showing specific
interaction between Y174A PBF and CTTN in TPC-1 and MD-MBA-231
cells vs WT PBF. Magnification, 63
. Scale bars, 10 M. White
indicates DAPI nuclear staining in panels B–D, F, and H.
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Figure 6. Phosphorylation is critical to the functional interaction of PBF with CTTN. A, Representative 2D Boyden assay chamber cell invasion
assay from three independent experiments showing TPC-1 cells transfected with VO, WT PBF, or Y174A PBF; representative photomicrographs are
shown (i), as well as Western blots to confirm transfection (ii). Results are expressed as mean  SEM. *, P  .05; **, P  .01. B, Representative 3D
organotypic invasion assays in MDA-MB-231 cells transfected with VO, WT PBF or Y174A PBF. Box-whisper plots (right) show quantification of
invasion area of MDA-MB-2331 cells. Statistics analyzed using Mann-Whitney U test. **, P  .01; ***, P  .001. C, Co-IP assays in HeLa cells
transfected with VO, WT PBF, Y174A PBF, or CTTN as indicated and then treated with 50nM dasatinib () or vehicle (). D, Quantification of
scratch wound assay in MCF-7 cells stably transfected with VO, WT PBF, or Y174A PBF. Cells were treated with 50nM dasatanib (black) or vehicle
(white) and percent wound recovery determined at the indicated time point postrecovery (h). Results are expressed as mean  SEM. *, P  .05;
**, P  .01; ***, P  .001. E, Schematic representation summarizing the proposed mechanism of PBF binding to CTTN and regulating tumor cell
invasion. Proinvasive: (i) Src phosphorylates PBF and CTTN thereby promoting their interaction and actin filament assembly via downstream
partners such as Arp2/3. Inhibitory: (ii) Dasatinib inhibits tyrosine phosphorylation by Src and diminishes binding between PBF and CTTN. (iii)
Ablating phosphorylation at residue Y174 inactivates PBF and impairs the induction of tumor cell invasion.
doi: 10.1210/jc.2016-1932 press.endocrine.org/journal/jcem 4561
were capable of up-regulating the other. Previously, am-
plification of the gene that encodes CTTN has been re-
ported in approximately 15% of primary metastatic
breast carcinomas and approximately 30% of head and
neck squamous cell carcinomas (28). Thus, the apparent
inductionofCTTNinDTCmaybe via gene amplification,
or other gene regulatory mechanisms. Notwithstanding
this, CTTN overexpression has been extensively linked to
invasive cancers, including melanoma, colorectal cancer,
and glioblastoma (8, 29, 30). Future studies will need to
determine whether intratumoral heterogeneity stemming
from genetic and nongenetic variability influences the ex-
pression and colocalization of CTTN and PBF.
Arguably the central challenge inhuman tumor therapy
is to identify robust mechanisms of inhibiting cellular in-
vasion and metastasis. To this end we appraised PBF as a
gene which might represent a therapeutic paradigm in the
attenuation of CTTN function. PBF shows the structural
hallmarks of being an-helical integralmembraneprotein
(19), which continually shuttles to and from the PM (21).
When we ’locked’ PBF at the PM by disrupting its inter-
nalisation motif, we blocked the invasive capacity of cells
in vitro, which was accompanied by significantly in-
creased PBF:CTTN binding. CTTN regulates membrane
trafficking as well as adhesion dynamics (8, 13), and PBF
is intimately involved in both processes (21, 23, 31). Stud-
ies will need to address the potential cooperativity of PBF
and CTTN in membrane trafficking and cytoplasmic lo-
calization, and whether the kinase pathways known to
modulate aspects of PBF and CTTN function overlap in
vitro and in vivo.
The principle sites of tyrosine phosphorylation of
CTTN are Y421 and Y466, within the proline-rich do-
main (9). Src kinase phosphorylation at Y421 andY466 is
associated with lamaellipodial protrusions and recruit-
ment of SH2 domain proteins such as Arg and NCK1,
which links CTTN with N-WASP and WIP, and leads to
enhanced activation of the Arp2/3 complex (32, 33). Of
note, tyrosine phosphorylation of CTTN is also required
for the endocytosis of several receptors (34). This is par-
alleled by one of the central functions of PBF, which is the
regulation of the internalisation of PM proteins such as
NIS (23, 31), and which is governed by tyrosine phos-
phorylation.We therefore attempted to define the effect
of altered PBF phosphorylation on CTTN function via
mutagenesis and dasatinib treatment. Key among da-
satinib’s established targets is Src, which phosphory-
lates both CTTN (9) and PBF (23). However, given that
dasatinib has a range of targets and functions (35), dis-
entangling the chronology and relative contribution of
Src inhibition to altered CTTN and PBF function is
challenging.
We thereforeusedaphospho-null PBFmutant (Y174A)
in our dasatinib experiments to discriminate CTTN phos-
phorylation events fromPBFphosphorylation. These data
demonstrated that inhibiting Src reduced phosphoryla-
tion of CTTN at Y421 and decreased binding to PBF.
Previous studies showed that Src phosphorylation of
CTTN can increase its binding affinity to other binding
partners such as Dynamin 2 by more than 3-fold (34).
These findings are therefore supportive that tyrosinephos-
phorylation of CTTN promotes binding to PBF. Experi-
ments to further define the role of Src phosphorylation at
multiple sites in CTTN will be needed using phosphosite
mutations at positions Y421 and Y466. From the PBF
side, colocalization of pY174 PBF and CTTN was dem-
onstrated at the PM, along with specific binding by co-IP
analysis. Therefore, together with the lack of cellular in-
vasion observed with Y174A PBF, these results suggest
that phosphorylation of PBF at Y174 is required for a
functional interaction with CTTN at the PM to mediate
cell invasion.
Interestingly, Y174A PBF bound CTTN with a higher
affinity thanWTPBF.Our study inferred a role for PBF as
a molecular scaffold or bridging molecule to promote the
recruitment of CTTNwith other CTTN-binding partners
such as Src or the Arp2/3 complex and facilitate actin
filament assembly. Y174A PBF might have therefore an-
tagonized CTTN activity by blocking critical interactions
with one or more recognized CTTN-binding partners due
to its greater affinity for CTTN and increased retention at
the PM. It is also likely that the altered properties of
Y174APBFwouldhavedelayed thedynamic regulationof
the cortical actin cytoskeleton required for cell migration
associated with multiple cycles of actin polymerization
and depolymerization to generate the propulsive force
needed for lamellipodia extension (10).
In summary, we present evidence that the proto-onco-
gene PBF is a novel interacting partner of the F-actin bind-
ing protein CTTN. PBF potently and consistently induces
cell invasion and migration, which is dependent upon the
presence of CTTN. As PBF and CTTN are induced in
multiple tumor types, our study now identifies PBF as an
undercharacterized target to block tumor cell movement.
Ablating phosphorylation by mutation or treatment with
a tyrosine kinase inhibitor modulates the interaction of
PBFwithCTTNand attenuates cell invasion.Hence, ther-
apeutic strategies to manipulate the PBF:CTTN interac-
tion need to be further appraised as promising new ave-
nues in the treatment of endocrine tumor metastasis.
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